Abstract Number: 1583 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis
Background/Purpose: High BMI is associated with reduced remission rates with anti-TNF agents in RA.1,2 In ACQUIRE (NCT00559585), SC and IV abatacept (ABA) achieved similar ACR20…Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting
Bari-00074565
Background/Purpose: Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…Abstract Number: 1585 • 2016 ACR/ARHP Annual Meeting
Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Background/Purpose: Baricitinib (BARI), an oral JAK1/JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA.1,2 The purpose of this post hoc analysis…Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…Abstract Number: 1587 • 2016 ACR/ARHP Annual Meeting
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)
Methods: 47 adult female RA subjects were randomized 1:1 CC-292 375 mg PO daily or placebo (PBO). Subjects were required to have a diagnosis of…Abstract Number: 1588 • 2016 ACR/ARHP Annual Meeting
Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
Background/Purpose: Costimulation through the CD40–CD40L axis is implicated in the pathogenesis of RA including T cell-mediated responses, B cell-driven autoantibodies, adhesion molecule expression, synovial hyperplasia…Abstract Number: 1589 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
Background/Purpose: In patients with RA, obesity may impair clinical response to anti-TNF agents.1,2 In contrast, BMI does not appear to impact treatment retention or clinical…Abstract Number: 1590 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA. Drug-related problems are common in…Abstract Number: 1591 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor under investigation for the treatment of patients (pts) with moderate to severe RA.1-2 In the 52-week Phase…Abstract Number: 1592 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week
Background/Purpose: The non-inferiority of subcutaneous tocilizumab (TCZ-SC) monotherapy every 2 weeks (q2w) to intravenous TCZ monotherapy every 4 weeks was demonstrated in Japanese patients with…Abstract Number: 1593 • 2016 ACR/ARHP Annual Meeting
Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Baricitinib is a small molecule inhibitor of the Janus kinase (JAK) pathways that reduce and modulate the production of inflammatory mediators and cytokines. We…Abstract Number: 1594 • 2016 ACR/ARHP Annual Meeting
First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Background/Purpose: Spleen Tyrosine Kinase (SYK) mediates immunoreceptor signaling in a range of hematopoietic cells important for the initiation and progression of inflammatory diseases such as…Abstract Number: 1595 • 2016 ACR/ARHP Annual Meeting
Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Solo1 and ORAL Sync2 are two Phase 3 index studies that…Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…Abstract Number: 1597 • 2016 ACR/ARHP Annual Meeting
Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab
Background/Purpose: Olokizumab (OKZ) is an anti-interleukin-6 (IL-6) monoclonal antibody in development for the treatment of rheumatoid arthritis (RA). In phase 2 studies, treatment with OKZ+methotrexate…
ACR Meeting Abstracts